Next Article in Journal
Interplay between Cellular Autophagy and Hepatitis B Virus Replication: A Systematic Review
Previous Article in Journal
Increased Uptake of Silica Nanoparticles in Inflamed Macrophages but Not upon Co-Exposure to Micron-Sized Particles
Review

Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?

1
Nuclear Signaling Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Monash, Victoria 3800, Australia
2
Cancer Targeting and Nuclear Therapeutics Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Monash, Victoria 3800, Australia
*
Author to whom correspondence should be addressed.
Cells 2020, 9(9), 2100; https://doi.org/10.3390/cells9092100
Received: 8 August 2020 / Revised: 4 September 2020 / Accepted: 9 September 2020 / Published: 15 September 2020
(This article belongs to the Section Cell Nuclei: Function, Transport and Receptors)
The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug Administration for parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an antiviral. It was identified in a high-throughput chemical screen as inhibiting recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1) integrase protein by the host heterodimeric importin (IMP) α/β1 complex, and has since been shown to bind directly to IMPα to induce conformational changes that prevent its normal function in mediating nuclear import of key viral and host proteins. Excitingly, cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, Venezuelan equine encephalitis virus, Chikungunya virus, Pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Phase III human clinical trials have been completed for DENV, with >50 trials currently in progress worldwide for SARS-CoV-2. This mini-review discusses the case for ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. View Full-Text
Keywords: ivermectin; antiviral; SARS-CoV-2; COVID-19; flavivirus; dengue virus; Zika virus ivermectin; antiviral; SARS-CoV-2; COVID-19; flavivirus; dengue virus; Zika virus
Show Figures

Figure 1

MDPI and ACS Style

Jans, D.A.; Wagstaff, K.M. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells 2020, 9, 2100. https://doi.org/10.3390/cells9092100

AMA Style

Jans DA, Wagstaff KM. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells. 2020; 9(9):2100. https://doi.org/10.3390/cells9092100

Chicago/Turabian Style

Jans, David A., and Kylie M. Wagstaff. 2020. "Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?" Cells 9, no. 9: 2100. https://doi.org/10.3390/cells9092100

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop